Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 9/20 | 0.69 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12060508 | 1.00 | VDR (0.69) | VDRHDAC3HDAC6HDAC2 | |
| SCHEMBL14107792 | 0.91 | VDR (0.70) | VDR | |
| SCHEMBL9010457 | 0.90 | VDR (0.69) | VDR | |
| SCHEMBL12712505 | 0.90 | VDR (0.69) | VDR | |
| Paricalcitol SCHEMBL25447329 | 0.88 | VDR (0.68) | VDRHDAC3HDAC6HDAC2 | |
| Paricalcitol SCHEMBL17354891 | 0.88 | VDR (0.68) | VDRHDAC3HDAC6HDAC2 | |
| Paricalcitol SCHEMBL12397908 | 0.88 | VDR (0.68) | VDRHDAC3HDAC6HDAC2 | |
| Paricalcitol SCHEMBL14491013 | 0.88 | VDR (0.68) | VDRHDAC3HDAC6HDAC2 | |
| Paricalcitol SCHEMBL21836180 | 0.88 | VDR (0.68) | VDRHDAC3HDAC6HDAC2 | |
| Paricalcitol SCHEMBL6945983 | 0.88 | VDR (0.68) | VDRHDAC3HDAC6HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093458-A1 | Preparation of paricalcitol and crystalline forms thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093458-A1 | Preparation of paricalcitol and crystalline forms thereof | PTH1R, CYP24A1, CYP2R1 | VDR 4/4885HDAC3 4357/4885HDAC6 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.